FDA
-
-
-
-
-
-
-
FDA notifies Invivyd that Pemgarda EUA will end June 2027
-
-
-
-
-
-
-
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safe
-
-
-
-
-
-
-
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
-
-
-
-
-
-
-
Invivyd Announces Presentation at the World Vaccine Congress Washington
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)
-
-
-
-
-
-
-
Invivyd reports $17.2 million Q4 revenue, up 25% year-over-year
-
-
-
-
-
-
-
Invivyd identifies RSV antibody candidate VBY329 for pediatric prevention
-
330,123 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

